Here's how i think about it.
Current market cap is $285mn.
Scott previously from 51Cap suggested the MPS asset could be worth up to $1bn as a deal and $10bn for full asset. This no doubt includes all lysosomal diseases. Who knows if these numbers are reasonable.
So if they can land a deal for MPS (with good trial results) above $285mn, in a way you have a free option on KOA. The company becomes MASSIVELY derisked.
What's the KOA asset worth- $4-$5+bn U.S.? Probably going to be another 2 years before we find that out.
So I want to see that MPS asset value realised in next 9-12 months.
I expect to see weakness in share price due to tax loss selling like last year and may top up then.
- Forums
- ASX - By Stock
- PAR
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-368
-
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 143324 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 44935 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 143324 | 0.200 |
9 | 191984 | 0.195 |
15 | 199884 | 0.190 |
6 | 161140 | 0.185 |
16 | 784128 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 44935 | 3 |
0.215 | 132157 | 4 |
0.220 | 82155 | 7 |
0.225 | 31604 | 3 |
0.230 | 33834 | 4 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online